# Chiasma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chiasma

- Industry: Pharmaceuticals
- Headquarters: Jerusalem, Israel
- Website: chiasmapharma.com
- Total disclosed funding: $173M
- Latest round: Series E (Feb 27, 2015)
- Investors on record: 11

## About

Chiasma is a biopharmaceutical company focused on developing innovative therapeutics to improve patient outcomes. They specialize in transforming the treatment of chronic diseases through unique delivery systems and formulations.Chiasma, founded in 2001 in Jerusalem, Israel, is a biopharmaceutical company dedicated to improving the lives of patients with chronic diseases. The company was co-founded by Asif Abbas and Marcel Craven. Chiasma raised USD 102 mn through an IPO in July 2015, offering 6.4 million shares at USD 16 per share on the NASDAQ, marking a significant milestone in their funding journey.Chiasma specializes in delivering innovative therapeutic solutions, particularly in the biopharmaceutical sector. Their core product offerings focus on advanced drug delivery systems designed to enhance patient compliance and treatment efficacy. These products address specific challenges in the management of chronic diseases, ensuring patients receive effective therapies while minimizing the complexity of treatment regimens. The company’s solutions cater to various healthcare sectors, demonstrating their adaptability and commitment to patient-centric care.Chiasma operates on a revenue model primarily geared towards pharmaceutical sales, providing access to groundbreaking therapies through specialized distribution channels. Their strategic partnerships with healthcare providers ensure that their innovative products reach patients effectively. The company's pricing plans are structured to accommodate diverse healthcare systems and patient needs, contributing to a stable revenue flow.Chiasma is focused on expanding its product line with planned launches of new therapies designed to address unmet medical needs in chronic disease management by 2025. The company is strategically targeting expansion into markets in Europe and Asia-Pacific to leverage increasing demand for innovative biopharmaceutical solutions. The funds raised in the recent IPO will support these growth initiatives, facilitating research and development efforts and market entry strategies.

## Funding rounds

- Series E, Feb 27, 2015, $70M — Abingworth, ARCH Venture Partners, Sofinnova Investments, 7 Health Ventures, MPM BioImpact, F2 Ventures, Rock Springs Capital
- Series D, Jul 23, 2012, $39M — Abingworth, ARCH Venture Partners, MPM BioImpact, F3 Ventures
- Series B, Jan 13, 2009, $11M — ARCH Venture Partners, MPM BioImpact, F2 Ventures, XT Investments
- Series B, May 15, 2008, $2.9M — ARCH Venture Partners, Jerusalem Global Ventures, 7 Health Ventures, MPM BioImpact
- Series C, Nov 15, 2006, $44M — ARCH Venture Partners, MPM BioImpact, F2 Ventures, XT Investments
- Series B, Sep 12, 2005, $6.2M — Jerusalem Global Ventures, F2 Ventures, XT Investments, Yissum Research Development

## Investors

- Jerusalem Global Ventures (https://capitalatlas.ai/funds/jerusalem-global-ventures) — Series B
- F2 Ventures (https://capitalatlas.ai/funds/f2-ventures) — Series B, Series C, Series E
- XT Investments (https://capitalatlas.ai/funds/xt-investments) — Series B, Series C
- Yissum Research Development — Series B
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series C, Series B, Series D, Series E
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series C, Series B, Series D, Series E
- 7 Health Ventures (https://capitalatlas.ai/funds/7-health-ventures) — Series B, Series E
- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series D, Series E
- F3 Ventures — Series D
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series E
- Rock Springs Capital — Series E